Mimicking nature’s antibodies

Monoclonal antibodies (mAbs) synthesised in the laboratory aim to mimic natural antibodies which are produced by the body to selectively 和 specifically target pathogenic proteins or antigens in response to infection 和 neutralise them. When used as a therapeutic, mAbs employ the same approach to seek out 和 neutralise the target of interest.

Over the past three decades, mAbs have revolutionised the treatment of infectious diseases, cancer 和 chronic immunological diseases. Building on our long-st和ing heritage in this field from 剑桥 Antibody Technology (CAT) 和 MedImmune, we harness our extensive antibody discovery 和 protein engineering platform to design mAbs for therapeutic applications. 例如, we are able to optimise mAbs using our proprietary extended half-life technology which can extend the length of protection of the mAbs in the body. We are also using these platforms to design 马伯片段 和 双特异性马伯, which can potentially offer wider therapeutic benefits unique to these modalities.

In addition to uncovering innovative ways to incorporate antibodies in cutting-edge therapies 和 diagnostics across oncology, we are developing novel mAbs that can target different drivers of inflammation in a number of respiratory 和 immunological conditions such as asthma 和 chronic obstructive pulmonary disease (COPD), as well as against infectious diseases such as respiratory syncytial virus (RSV) 和 COVID-19.^1,2

参考文献

1. Griffin MP, Yuan Y, Takas T, et al. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants [published correction appears in [英]医学. 2020年7月29日;:]. [英]医学. 2020;383(5):415-425. doi: 10.1056/NEJMoa1913556.

2. Zost SJ, Gilchuk P, Case JB, et al. Potently neutralizing 和 protective human antibodies against SARS-CoV-2 [published online ahead of print, 2020年7月15日]. 自然. 2020;10.1038/s41586-020-2548-6. doi: 10.1038/s41586-020-2548-6.